http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0132769-B1

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-26
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-625
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-625
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62
filingDate 1984-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1988-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1988-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0132769-B1
titleOfInvention Pharmaceutical formulation for the treatment of diabetes mellitus
abstract The invention relates to medicaments consisting of a physiologically acceptable excipient and an active compound combination of (a) an insulin derivative of the formula I <IMAGE> (I) in which R1 denotes H or H-Phe, R30 represents the radical of a neutral L-aminoacid and R31 represents a physiologically acceptable organic group of basic character with up to 50 carbon atoms, with an isoelectric point between 5.8 and 8.5, and (b) an insulin of the formula I in which R1 denotes H or H-Phe, R30 represents Ala, Thr or Ser and R31 denotes OH, and to its use for the treatment of diabetes mellitus.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9408893-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6004938-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7452860-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9364519-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5149716-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5028587-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0347781-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5622934-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7696162-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0280534-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0280534-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5624903-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5177058-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0347781-A2
priorityDate 1983-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399382
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID235971415
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226432315
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3032849
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226432314
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18927055
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3641960
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226457782
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409109
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393519
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394044
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID69651
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88655036
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226432313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7708
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6140
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18394836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5585
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399383

Total number of triples: 50.